Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China.

ABSTRACT:

Background

Pleural mesothelioma (PM) has a poor prognosis, and immune checkpoint inhibitors (ICIs) have reshaped first-line therapy. However, real-world data comparing first-line immunotherapy with chemotherapy ± targeted therapy and defining optimal second-line strategies in Chinese patients remain limited. This multicenter retrospective real-world study aimed to compare survival outcomes between first-line immunotherapy and chemotherapy-based regimens and to evaluate the effectiveness of different subsequent systemic therapies in patients with PM.

Methods

This multicenter retrospective real-world cohort included patients with pathologically confirmed PM who received at least one line of systemic therapy at tertiary hospitals in China between January 2015 and January 2025.

SUBMITTER: Tian B 

PROVIDER: S-EPMC12775688 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature